Sei Investments Co. Invests $1.43 Million in Eton Pharmaceuticals, Inc. $ETON

Key Points

• Sei Investments Co. acquired a new $1.43 million stake in Eton Pharmaceuticals, buying 58,034 shares and owning approximately 0.21% of the company. Institutional investors collectively hold 27.86% of Eton’s stock.
• Analyst sentiment remains mixed but leans positive: Eton has a consensus “Moderate Buy” rating and an average price target of $52.50, while individual targets range from $57 to $62 alongside a “Strong Sell” downgrade from Zacks Research.
• Eton reported quarterly revenue of $24.27 million, exceeding estimates, but earnings of $0.05 per share missed expectations of $0.10. Meanwhile, insiders sold 150,000 shares worth approximately $4.85 million over the past 90 days.

Sei Investments Co. bought a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 58,034 shares of the company's stock, valued at approximately $1,432,000. Sei Investments Co. owned 0.21% of Eton Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Walleye Capital LLC bought a new stake in Eton Pharmaceuticals in the first quarter valued at $2,023,000. Jefferies Financial Group Inc. raised its holdings in Eton Pharmaceuticals by 33.8% in the 4th quarter. Jefferies Financial Group Inc. now owns 118,300 shares of the company's stock worth $2,000,000 after purchasing an additional 29,860 shares in the last quarter. Intech Investment Management LLC raised its holdings in Eton Pharmaceuticals by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company's stock worth $210,000 after purchasing an additional 1,244 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth about $200,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth about $198,000. Institutional investors own 27.86% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ETON. Canaccord Genuity Group started coverage on shares of Eton Pharmaceuticals in a research report on Thursday, July 16th. They set a "buy" rating and a $60.00 price target on the stock. Wall Street Zen raised Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 13th. HC Wainwright upped their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a "buy" rating in a report on Friday, May 15th. Zacks Research lowered Eton Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Monday, July 13th. Finally, Craig Hallum raised their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $52.50.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of the firm's stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the sale, the insider directly owned 25,249 shares in the company, valued at approximately $794,586.03. This trade represents a 43.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $1,624,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by company insiders.

Eton Pharmaceuticals Trading Down 2.1%

Eton Pharmaceuticals stock opened at $43.67 on Tuesday. Eton Pharmaceuticals, Inc. has a 12 month low of $14.27 and a 12 month high of $50.18. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -623.77 and a beta of 0.86. The business's fifty day simple moving average is $37.66 and its two-hundred day simple moving average is $27.82. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The company had revenue of $24.27 million for the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, equities analysts predict that Eton Pharmaceuticals, Inc. will post 0.75 earnings per share for the current fiscal year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source